Allogene Therapeutics

OverviewSuggest Edit

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer. The Company's portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

TypePublic
Founded2018
HQSouth San Francisco, CA, US
Websiteallogene.com
Employee Ratings4.7

Latest Updates

Employees (est.) (Feb 2020)205(+8%)
Job Openings27
Share Price (May 2021)$30.6
Cybersecurity ratingBMore

Key People/Management at Allogene Therapeutics

Arie Belldegrun

Arie Belldegrun

Director
David Chang

David Chang

President, Chief Executive Officer and Co-Founder, Director
David Bonderman

David Bonderman

Director
Alison Moore

Alison Moore

Chief Technical Officer
Barbra Sasu

Barbra Sasu

Chief Scientific Officer
Debbie Messemer

Debbie Messemer

Director
Show more

Allogene Therapeutics Office Locations

Allogene Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
210 E Grand Ave
Show all (1)

Allogene Therapeutics Financials and Metrics

Allogene Therapeutics Revenue

USD

Net income (FY, 2020)

(250.2m)

EBIT (FY, 2020)

(258.2m)

Market capitalization (3-May-2021)

4.3b

Closing stock price (3-May-2021)

30.6

Cash (31-Dec-2020)

183.4m

EV

4.2b
Allogene Therapeutics's current market capitalization is $4.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

2.0k41.0m57.5m65.3m

R&D expense

151.9m144.5m193.0m

Operating expense total

2.0k192.8m202.0m258.2m

EBIT

(2.0k)(192.8m)(202.0m)(258.2m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

2.6m12.5m11.3m13.1m14.2m15.0m15.6m15.9m16.6m

R&D expense

122.5m10.9m23.4m31.8m40.0m42.0m47.3m51.4m

Operating expense total

2.6m135.0m22.2m36.5m46.0m55.0m57.7m63.2m68.0m

EBIT

(2.6m)(135.0m)(22.2m)(36.5m)(46.0m)(55.0m)(57.7m)(63.2m)(68.0m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.4m175.1m183.4m

Prepaid Expenses

17.2m

Current Assets

468.0m544.6m845.1m

PP&E

8.6m56.4m118.8m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

143.9m83.1m92.7m112.6m161.0m135.9m280.4m158.1m

Prepaid Expenses

11.5m9.9m13.0m

Current Assets

144.3m247.4m476.6m511.5m509.8m504.4m909.6m854.1m

PP&E

3.5m4.7m20.4m35.8m45.9m66.3m84.6m102.7m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.0k)(211.5m)(184.6m)(250.2m)

Depreciation and Amortization

1.5m5.0m7.6m

Accounts Payable

8.8m(985.0k)615.0k

Cash From Operating Activities

(44.7m)(137.3m)(115.1m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.6m)(137.5m)(181.0m)(31.6m)(72.8m)(123.6m)(54.5m)(115.5m)(181.7m)

Depreciation and Amortization

450.0k953.0k695.0k1.8m3.2m2.0m3.9m5.7m

Accounts Payable

1.3m3.1m(348.0k)1.3m(3.1m)(1.0m)(503.0k)1.7m

Cash From Operating Activities

5.0k(6.0m)(23.2m)(30.3m)(55.1m)(87.1m)(40.8m)(67.5m)(105.1m)
Show all financial metrics

Allogene Therapeutics Operating Metrics

Sep, 2018FY, 2018FY, 2019

Patients Included in Clinical Trials

182121

Pre-Clinical Phase Products

778

Phase I Trials Products

114

Office and Laboratory Space, square feet

89.54 k222.49 k200.94 k
Show all operating metrics

Allogene Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Allogene Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Allogene Therapeutics Online and Social Media Presence

Embed Graph

Allogene Therapeutics News and Updates

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an i…

Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) gran…

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has…

Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks Therap…

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical data at the American Association for Canc…
Show more

Allogene Therapeutics Blogs

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Content Import Thu, 02/25/2021 - 16:04 Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Feb 25, 2021 at 4:02 PM EST …

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma

Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma Content Import Wed, 12/23/2020 - 11:30 Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Admi…

Allogene Therapeutics Reports Third Quarter 2020 Financial Results

Allogene Therapeutics Reports Third Quarter 2020 Financial Results Content Import Wed, 11/04/2020 - 07:31 Allogene Therapeutics Reports Third Quarter 2020 Financial Results Nov 4, 2020 at 7:30 AM EST This release is a backfill from a News Wire E…

Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation

Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation Content Import Wed, 09/02/2020 - 08:31 Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation Sep 2, 2020 at 8:30 AM EDT This release is …

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize

Dr. Schumacher Awarded Prestigious Academic Prize in the Netherlands for Research in Cancer Immunotherapy SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR

Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting

Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting Content Import Mon, 06/22/2020 - 16:30 Allogene Therapeutic…
Show more

Allogene Therapeutics Frequently Asked Questions

  • When was Allogene Therapeutics founded?

    Allogene Therapeutics was founded in 2018.

  • Who are Allogene Therapeutics key executives?

    Allogene Therapeutics's key executives are Arie Belldegrun, David Chang and David Bonderman.

  • How many employees does Allogene Therapeutics have?

    Allogene Therapeutics has 205 employees.

  • Who are Allogene Therapeutics competitors?

    Competitors of Allogene Therapeutics include Bellicum Pharmaceuticals, Plus Therapeutics and Legend Biotech.

  • Where is Allogene Therapeutics headquarters?

    Allogene Therapeutics headquarters is located at 210 E Grand Ave, South San Francisco.

  • Where are Allogene Therapeutics offices?

    Allogene Therapeutics has an office in South San Francisco.

  • How many offices does Allogene Therapeutics have?

    Allogene Therapeutics has 1 office.